These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31402562)

  • 1. miRNA expression changes during the course of neoadjuvant bevacizumab and chemotherapy treatment in breast cancer.
    Lindholm EM; Ragle Aure M; Haugen MH; Kleivi Sahlberg K; Kristensen VN; Nebdal D; Børresen-Dale AL; Lingjaerde OC; Engebraaten O
    Mol Oncol; 2019 Oct; 13(10):2278-2296. PubMed ID: 31402562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers.
    Haugen MH; Lingjærde OC; Hedenfalk I; Garred Ø; Borgen E; Loman N; Hatschek T; Børresen-Dale AL; Naume B; Mills GB; Mælandsmo GM; Engebraaten O
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.
    Hein A; Lambrechts D; von Minckwitz G; Häberle L; Eidtmann H; Tesch H; Untch M; Hilfrich J; Schem C; Rezai M; Gerber B; Dan Costa S; Blohmer JU; Schwedler K; Kittel K; Fehm T; Kunz G; Beckmann MW; Ekici AB; Hanusch C; Huober J; Liedtke C; Mau C; Moisse M; Müller V; Nekljudova V; Peuteman G; Rack B; Rübner M; Van Brussel T; Wang L; Weinshilboum RM; Loibl S; Fasching PA
    Int J Cancer; 2015 Dec; 137(12):2981-8. PubMed ID: 26100253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
    Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
    Rodgers M; Soares M; Epstein D; Yang H; Fox D; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():1-12. PubMed ID: 21609648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.
    Earl HM; Hiller L; Dunn JA; Blenkinsop C; Grybowicz L; Vallier AL; Gounaris I; Abraham JE; Hughes-Davies L; McAdam K; Chan S; Ahmad R; Hickish T; Rea D; Caldas C; Bartlett JMS; Cameron DA; Provenzano E; Thomas J; Hayward RL;
    Ann Oncol; 2017 Aug; 28(8):1817-1824. PubMed ID: 28459938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
    Silwal-Pandit L; Nord S; von der Lippe Gythfeldt H; Møller EK; Fleischer T; Rødland E; Krohn M; Borgen E; Garred Ø; Olsen T; Vu P; Skjerven H; Fangberget A; Holmen MM; Schlitchting E; Wille E; Nordberg Stokke M; Moen Vollan HK; Kristensen V; Langerød A; Lundgren S; Wist E; Naume B; Lingjærde OC; Børresen-Dale AL; Engebraaten O
    Clin Cancer Res; 2017 Aug; 23(16):4662-4670. PubMed ID: 28487444
    [No Abstract]   [Full Text] [Related]  

  • 9. An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer.
    Fleischer T; Haugen MH; Ankill J; Silwal-Pandit L; Børresen-Dale AL; Hedenfalk I; Hatschek T; Tost J; Engebraaten O; Kristensen VN
    Mol Oncol; 2024 Aug; 18(8):2042-2059. PubMed ID: 38671580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.
    Höglander EK; Nord S; Wedge DC; Lingjærde OC; Silwal-Pandit L; Gythfeldt HV; Vollan HKM; Fleischer T; Krohn M; Schlitchting E; Borgen E; Garred Ø; Holmen MM; Wist E; Naume B; Van Loo P; Børresen-Dale AL; Engebraaten O; Kristensen V
    Genome Med; 2018 Nov; 10(1):92. PubMed ID: 30497530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.
    Vaklavas C; Roberts BS; Varley KE; Lin NU; Liu MC; Rugo HS; Puhalla S; Nanda R; Storniolo AM; Carey LA; Saleh MN; Li Y; Delossantos JF; Grizzle WE; LoBuglio AF; Myers RM; Forero-Torres A;
    Breast Cancer Res; 2020 Feb; 22(1):22. PubMed ID: 32070401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study.
    Trédan O; Follana P; Moullet I; Cropet C; Trager-Maury S; Dauba J; Lavau-Denes S; Diéras V; Béal-Ardisson D; Gouttebel M; Orfeuvre H; Stefani L; Jouannaud C; Bürki F; Petit T; Guardiola E; Becuwe C; Blot E; Pujade-Lauraine E; Bachelot T
    Ann Oncol; 2016 Jun; 27(6):1020-1029. PubMed ID: 26916095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab.
    Wagenseller AG; Shada A; D'Auria KM; Murphy C; Sun D; Molhoek KR; Papin JA; Dutta A; Slingluff CL
    J Transl Med; 2013 Sep; 11():218. PubMed ID: 24047116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
    Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
    Sun Z; Lan X; Xu S; Li S; Xi Y
    BMC Cancer; 2020 Mar; 20(1):180. PubMed ID: 32131770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.
    Frères P; Josse C; Bovy N; Boukerroucha M; Struman I; Bours V; Jerusalem G
    J Cell Physiol; 2015 Feb; 230(2):473-81. PubMed ID: 25078559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation.
    Yagi T; Sawada K; Miyamoto M; Shimizu A; Oi Y; Toda A; Nakamura K; Kinose Y; Kodama M; Hashimoto K; Kimura T
    Mol Cancer Res; 2023 Oct; 21(10):1093-1106. PubMed ID: 37327051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
    Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
    Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does neoadjuvant bevacizumab increase surgical complications in breast surgery?
    Golshan M; Garber JE; Gelman R; Tung N; Smith BL; Troyan S; Greenberg CC; Winer EP; Ryan P
    Ann Surg Oncol; 2011 Mar; 18(3):733-7. PubMed ID: 20882415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.